Acrobiosystems Co

Acrobiosystems Co P/B

The P/B (Price-to-Book Ratio) of Acrobiosystems Co (301080.SZ) as of Nov 11, 2026 is 3.70. In the previous year, P/B (Price-to-Book Ratio) was 3.76 — a change of -1.58% (lower).

P/B

3.70

YoY

-1.58%

Last updated:

P/B (Price-to-Book Ratio) of Acrobiosystems Co is 2025 3.70 . P/B (Price-to-Book Ratio) of Acrobiosystems Co was 2024 3.76 . It decreases by -1.58% lower compared to the previous year.

The Acrobiosystems Co P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2018
134.30 CNY
Jan 1, 2019
101.09 CNY
Jan 1, 2020
49.15 CNY
Jan 1, 2021
3.99 CNY
Jan 1, 2022
3.84 CNY
Jan 1, 2023
3.80 CNY
Jan 1, 2024
3.76 CNY
Jan 1, 2025
3.70 CNY
The Acrobiosystems Co P/B history
YEARP/BYoY
3.70-1.58%
3.76-1.00%
3.80-1.02%
3.84-3.75%
3.99-91.88%
49.15-51.38%
101.09-24.72%
134.30—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acrobiosystems Co Stock analysis

What does Acrobiosystems Co do? Acrobiosystems Co Ltd develops biomedicine and bio-protein technology, focusing on recombinant proteins, detection services, kits, antibodies, fillers, and culture media. The company serves R&D and production sectors for drug discovery, screening, diagnostic reagents, and clinical trials across tumor, autoimmune, cardiovascular, and infectious disease areas. Its products support early drug development stages and process control in pharmaceutical manufacturing. The firm's main customers are pharmaceutical companies and research institutions requiring advanced biotech solutions for disease treatment development. The company generates revenue through the sale of recombinant proteins, detection services, and related products like kits and antibodies. These offerings are tailored for pharmaceutical firms engaged in drug development and diagnostic reagent optimization. Acrobiosystems' product portfolio targets the biopharmaceutical industry, specifically addressing needs in tumor, autoimmune, cardiovascular, and infectious disease research. The firm's services are utilized in preclinical and clinical trial phases to enhance drug development efficiency. Acrobiosystems' main products include recombinant proteins, kits, antibodies, fillers, and culture media, which are sold to pharmaceutical companies and research organizations. These entities use the products for early-stage drug discovery, verification, and optimization processes. The company's detection services support diagnostic reagent development and drug screening, directly contributing to the pharmaceutical R&D pipeline. The firm's focus on CMC (process control) for drug production ensures its offerings align with critical manufacturing stages in biopharmaceutical development. Acrobiosystems Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acrobiosystems Co stock

P/B (Price-to-Book Ratio) of Acrobiosystems Co is 3.70 in 2025.

P/B (Price-to-Book Ratio) of Acrobiosystems Co changed from 3.76 to 3.70, representing a -1.58% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Acrobiosystems Co since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Acrobiosystems Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Acrobiosystems Co

All Key Metrics — Acrobiosystems Co